Circulating Interleukin-15 and Rantes Chemokine in Parkinsonõs Disease Introduction

Interleukin‐15 promotes T‐cell proliferation, induction of cytolytic effector cells including natural killer (NK) and cytotoxic cells and stimulates B‐cell to proliferate and secrete immunoglobulins. RANTES is a C‐C beta chemokine with strong chemoattractant activity for T lymphocytes and monocytes.

[1]  P S Whitton,et al.  Inflammation as a causative factor in the aetiology of Parkinson's disease , 2007, British journal of pharmacology.

[2]  S. Tufik,et al.  Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats , 2006, Brain Research.

[3]  R. Uitti,et al.  Alterations of T-lymphocyte populations in Parkinson disease. , 2005, Parkinsonism & related disorders.

[4]  D. Gambi,et al.  Expression and production of two selected beta-chemokines in peripheral blood mononuclear cells from patients with Alzheimer's disease , 2005, Experimental Gerontology.

[5]  Z. Stelmasiak,et al.  The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease , 2005, European journal of neurology.

[6]  V. Álvarez,et al.  Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease , 2004, Neuroscience Letters.

[7]  D. Comings,et al.  RANTES: a genetic risk marker for multiple sclerosis , 2004, Multiple sclerosis.

[8]  C. Palmer,et al.  Differential expression of chemokines and chemokine receptors during microglial activation and inhibition , 2004, Journal of Neuroimmunology.

[9]  Makoto Sawada,et al.  Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains , 2003, Acta Neuropathologica.

[10]  R. Fernandez-Botran,et al.  The enhancement of T cell proliferation by l-dopa is mediated peripherally and does not involve interleukin-2 , 2003, Journal of Neuroimmunology.

[11]  S. Gangemi,et al.  Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease. , 2003, Mediators of inflammation.

[12]  Nick C Fox,et al.  Influence of monocyte chemoattractant protein 1 gene polymorphism on age at onset of sporadic Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[13]  R. Fernandez-Botran,et al.  In vivo administration of l-dopa or dopamine decreases the number of splenic IFNγ-producing cells , 2003, Journal of Neuroimmunology.

[14]  V. Appay,et al.  RANTES: a versatile and controversial chemokine. , 2001, Trends in immunology.

[15]  Bernhard Moser,et al.  Lymphocyte traffic control by chemokines , 2001, Nature Immunology.

[16]  S. Basu,et al.  Dopamine, a neurotransmitter, influences the immune system , 2000, Journal of Neuroimmunology.

[17]  Shuxian Hu,et al.  Inhibition of microglial cell RANTES production by IL‐10 and TGF‐β , 1999, Journal of leukocyte biology.

[18]  K. Blomgren,et al.  Chemokine and Inflammatory Cell Response to Hypoxia-Ischemia in Immature Rats , 1999, Pediatric Research.

[19]  R. Djaldetti,et al.  IL-1β, IL-2, IL-6 and TNF-α production by peripheral blood mononuclear cells from patients with Parkinson's disease , 1999 .

[20]  T. Waldmann,et al.  IL-15 induces the expression of chemokines and their receptors in T lymphocytes. , 1999, Journal of immunology.

[21]  M. Johnstone,et al.  A central role for astrocytes in the inflammatory response to β-amyloid; chemokines, cytokines and reactive oxygen species are produced , 1999, Journal of Neuroimmunology.

[22]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[23]  W. Le,et al.  Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation , 1998, Journal of neuroscience research.

[24]  F. Chiodi,et al.  Induction of human immunodeficiency virus type 1 replication in human glial cells after proinflammatory cytokines stimulation: Effect of IFNγ, IL1β, and TNFα on differentiation and chemokine production in glial cells , 1998 .

[25]  A. Luster,et al.  Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.

[26]  Y. S. Lin,et al.  Effect of dopamine on immune cell proliferation in mice. , 1997, Life sciences.

[27]  A. Enk,et al.  Induction of IL-15 messenger RNA and protein in human blood-derived dendritic cells: a role for IL-15 in attraction of T cells. , 1997, Journal of immunology.

[28]  T. Molitor,et al.  Differential production of and migratory response to beta chemokines by human microglia and astrocytes. , 1997, The Journal of infectious diseases.

[29]  T. Nagatsu,et al.  Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease , 1996, Neuroscience Letters.

[30]  J. Bergquist,et al.  Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis , 1996, Immunology.

[31]  J. Satoh,et al.  Interleukin‐15 gene expression in human astrocytes and microglia in culture , 1996, Neuroreport.

[32]  A. Sher,et al.  Induction and regulation of IL-15 expression in murine macrophages. , 1996, Journal of immunology.

[33]  M. Caligiuri,et al.  Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor , 1994, The Journal of experimental medicine.

[34]  V. Fung,et al.  Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. , 1994, Science.

[35]  E. Dupont,et al.  Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence , 1994, Acta neurologica Scandinavica.

[36]  P. Carvey,et al.  The potential use of a dopamine neuron antibody and a striatal‐derived neurotrophic factor as diagnostic markers in Parkinson's disease , 1991, Neurology.

[37]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[38]  A. Dahlström,et al.  Antibodies in the CSF of a Parkinson patient recognizes neurons in rat mesencephalic regions. , 1986, Acta physiologica Scandinavica.

[39]  P. Riederer,et al.  Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain , 2005, Journal of Neural Transmission.

[40]  S. Hunot,et al.  Neuroinflammatory processes in Parkinson's disease , 2003, Annals of neurology.

[41]  R. Ransohoff,et al.  Sentries at the gate: chemokines and the blood-brain barrier. , 1999, Journal of neurovirology.

[42]  R. Ransohoff,et al.  Chemokines and chemokine receptors in CNS pathology. , 1999, Journal of neurovirology.

[43]  F. Chiodi,et al.  Induction of human immunodeficiency virus type 1 replication in human glial cells after proinflammatory cytokines stimulation: effect of IFNgamma, IL1beta, and TNFalpha on differentiation and chemokine production in glial cells. , 1998, Glia.

[44]  P. Riederer,et al.  Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. , 1995, Journal of neural transmission. Parkinson's disease and dementia section.

[45]  P. Riederer,et al.  Brain β2-microglobulin levels are elevated in the striatum in Parkinson's diseaselevels are elevated in the striatum in Parkinson's disease , 1995 .

[46]  R. Bouillon,et al.  Distribution of group-specific component/vitamin-D-binding protein subtypes in Saudi Arabia. , 1991, Human heredity.